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Background. Obesity is a growing epidemic with limited effective treatments and an important risk factor for several diseases such
as metabolic syndrome (MetS). In this study, we aimed to investigate the effect of 3-amino-1,2,4-triazole (ATZ), an inhibitor of
catalase and heme synthesis, in a murine model for MetS. Methods. Male C57BL/6 mice with high-fat diet-induced MetS
received ATZ (500mg·kg-1·24 h-1) for 12 weeks. Results. The HFD group showed increased blood pressure and body weight,
enhanced fat deposition accompanied by an increase in adipocyte diameter, and decreased lipolysis in white adipose tissue
(WAT). The expression of genes related to inflammation was increased in WAT of the HFD group. Concurrently, these mice
exhibited an increase in leptin, nonesterified fatty acid (NEFA), insulin, and glucose in plasma, coupled with glucose intolerance
and insulin resistance. Strikingly, ATZ prevented the increase in blood pressure and the HFD-induced obesity as observed by
lower body weight, WAT index, triglycerides, NEFA, and leptin in plasma. ATZ treatment also prevented the HFD-induced
increase in adipocyte diameter and even induced marked atrophy and the accumulation of macrophages in this tissue. ATZ
treatment also improved glucose metabolism by increasing glucose tolerance and insulin sensitivity, GLUT4 mRNA expression
in WAT in parallel to decreased insulin levels. Conclusions. In the context of HFD-induced obesity and metabolic syndrome, the
fat loss induced by ATZ is probably due to heme synthesis inhibition, which blocks adipogenesis by probably decreased
RevErbα activity, leading to apoptosis of adipocytes and the recruitment of macrophages. As a consequence of fat loss, ATZ
elicits a beneficial systemic antiobesity effect and improves the metabolic status.
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2020, Article ID 3025361, 14 pages
https://doi.org/10.1155/2020/3025361
1. Introduction
Obesity is a growing epidemic with limited effective treatments
and an important risk factor for several diseases such as the
metabolic syndrome (MetS). This condition is characterized
by a group of symptoms [1], including obesity, hypertension,
hypertriglyceridemia, dyslipidemia, glucose intolerance, and
insulin resistance [1, 2]. White adipose tissue (WAT), the pri-
mary lipid storage depot [3], is central to the development of
the MetS, while being a powerful endocrine organ [4].
Increased fat accumulation is closely related to cardiometabolic
diseases, and thereby, the control of fat deposition becomes
pivotal to maintain a healthy life [3]. Currently, one of themost
discussed theories that attempts to explain the pathological
conditions associated with MetS involves the participation of
oxidative stress, resulting from changes in redox state, with a
predominance of prooxidant systems over antioxidants [5].
3-Amino-1,2,4-triazole (ATZ) is a heterocyclic organic
compound widely used as a catalase inhibitor [6], a ubiqui-
tous enzyme which metabolizes H2O2 to oxygen and water.
Probably linked to its main function, this compound also
inhibits α-oxidation [7], fatty acid synthesis, and lipogenesis
in isolated hepatocytes. In human differentiated adipocytes,
ATZ treatment impaired the antioxidant defense system
and induced inflammation [8]. Park et al. [9] have demon-
strated that the pharmacological or genetic inhibition of cat-
alase alters macrophage activation and thereby induces
inflammation of adipose tissue, suggesting a novel role of
endogenous catalase in macrophage polarization in adipose
tissue. In animals, the median lethal dose (LD50), which
ensures low acute toxicity [10]. However, the doses vary
according to some species already studied: in mice, the LD50
was 11,000mg ·kg−1; in sheep, 4,000mg ·kg−1 was fatal; in rats,
no signs of toxicity with 4,080mg ·kg−1 were observed [11]; in
bacterial and cultured mammalian cells and rodents exposed
in vivo, the ATZ was not genotoxic [12]. Steinhoff and coau-
thors did not observe carcinogenic activity of ATZ in golden
hamsters or in mice fed with ATZ in a lifespan test at dietary
levels of 1, 10, and 100ppm (rg amitrole · g−1 food), until they
died spontaneously. However, in rats, thyroid and pituitary
gland tumors were detected, induced by ATZ [13].
ATZ also inhibits aminolevulinic acid dehydratase, a key
enzyme in heme synthesis. Heme activates the transcription
repressor RevErbα, which is essential for adipocyte differenti-
ation [14]. Thus, ATZ may inhibit adipogenesis by blocking
the synthesis of heme. It has been shown that ATZ induces
fat loss and decreases plasma triacylglycerol levels in mice
[15]. However, the relevance of this phenomenon in MetS,
as well as the mechanism by which ATZ induces fat loss, still
remain unclear. We have inquired if ATZ decreases lipid stor-
age by increasing inflammation and cell death, by decreasing
adipogenesis, and/or by lipolysis. To address these questions,
we used high-fat diet- (HFD-) induced MetS in mice, a widely
used model to test pharmacological effects on obesity [16].
2. Methods
2.1. Ethics Statement and Animal Care. All experiments
reported here have been conducted in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Ani-
mal Resources, National Academy Press, Washington, DC,
1996). The procedures were approved by the Ethical Commit-
tee of the Federal University of Alagoas (029/2014). All the
animals were housed in an animal facility on a 12-hour light/-
dark cycle, and food and water were available ad libitum.
2.2. Diets and Research Design. C57BL/6 male mice (4-6
weeks old) were randomly divided into three groups: a
control (CT, n = 7), which was fed with standard diet
(caloric intake = 11:8% fat), the second group was fed with
HFD (caloric intake = 58:4% fat, primarily lard) (HFD, n =
6), and the third group was fed with HFD treated by dietary
supplementation with ATZ (HFD+ATZ, n = 8; 500mg·kg-1
24 h-1). The HFD was prepared according to Nunes-Souza
et al. [16], and all components were purchased from Rhos-
ter® LTDA (São Paulo, Brazil) and Sigma® (Seelze, Ger-
many). The animals were evaluated during 20 weeks in
total. However, the treatment with ATZ (Sigma®, Seelze,
Germany) started at the beginning of the eighth week of
HFD feeding. The dose and mode of application of ATZ
administration were determined in a pilot experiment, which
indicated that 500mg·kg-1 of ATZ promotes lipolytic effect
and reduction of visceral adiposity (unpublished data). The
dose of ATZ was adjusted weekly, taking into account the
mean body weight and the food intake, which were assessed
weekly in a semianalytical scale.
2.3. In Vivo and In Vitro Experiments
2.3.1. Systolic Blood Pressure and Metabolic Assessments. At
the end of the treatment, the animals were adapted to a small
mouse holder during one week. The measurement of systolic
blood pressure was recorded by tail plethysmography
(PowerLab®, ADInstruments, Melbourne, Australia).
Intraperitoneal (i.p) glucose tolerance test (GTT) was car-
ried out in overnight-fasted mice (12 hours), and insulin toler-
ance test (ITT) was performed in overnight fed; both were
conducted accordingly as described previously [16]. The prod-
uct of fasting triglyceride and glucose levels (TyG index), a val-
idated and highly sensitive marker of insulin resistance, was
calculated using the following formula [17, 18]: TyG index =
Ln ½triglyceride ðmg · dL−1Þ × glucose ðmg · dL−1Þ/2.
2.3.2. Lipolysis
(1) In Vivo. In an independent group of animals in fed condi-
tions, the lipolysis in vivo was performed by administration
of 1mg·kg-1, i.p selective adrenergic β3-receptor agonist,
the CL-316,243 hydrate (C5976; Sigma-Aldrich®, Seelze,
Germany) [19, 20]. The blood was collected from tail vein
before the administration and after, in 15 and 30 minutes.
Nonesterified fatty acid (NEFA) was measured in plasma
and normalized by the white adipose tissue (WAT) index,
which was obtained after euthanasia.
(2) In Vitro. To determine the influence of ATZ (50mmmol
·L-1), catalase (1,200mL-1), and H2O2 (0.1mmmol·L-1) sepa-
rately, we performed the lipolysis in vitro in WAT collected
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from C57Bl/6 mice feeding chow diet. The tissue was incu-
bated in a medium of culture (DMEM, Gibco® 11880; Darm-
stadt, Germany) in a bath (37°C; 95% O2; 5% CO2) for 30
minutes for collection of basal time (time 0). Immediately after
that, the medium was imbibed with CL-316,243 0.1mM alone
and in combination with ATZ, CAT, and H2O2 separately.
The NEFA were measured in the medium in 0, 90, and 180
minutes of incubation and normalized by the amount of fat
used for stimulation.
2.4. Euthanasia and Ex Vivo Experiments. In fasted state, all
animals were anesthetized (100mg·kg-1 ketamine, 10mg·kg-
1xylazine, i.p). In the sequence, animals were euthanized by
exsanguination through the right ventricle puncture. Plasma
was obtained after blood centrifugation (2,150 g) at 4°C for
10 minutes. The epididymal and perirenal WAT, as well as
interscapular brown adipose tissue (BAT), were removed,
weighed, and stored at −80°C until further analysis. WAT
index was calculated using the following formula: WAT index
ð%Þ = ½ðepididymal fatðgÞ + perirenal fatðgÞÞ/ðbody weightðgÞÞ
∗ 100. The relative weight (%) of tissue was calculated using
the following formula: relative weight ð%Þ = ½ðtissueðgÞ/body
weightðgÞÞ ∗ 100. The right tibias were removed, and the
length was measured using a pachymeter.
2.4.1. Circulating Biochemical Analysis. Fasting total choles-
terol (TCOL), triglycerides (TG) (Labtest®, Lagoa Santa, Bra-
zil), and NEFA (Wako Chemicals GmbH®, Germany) levels
in plasma were assayed using commercial kits following the
manufacturers’ instructions and performed in a microplate
(Thermo Scientific®, Software 2.4 Multiskan Spectrum, Fin-
land). ELISA assays were used to measure insulin and leptin
levels (Millipore®, Schwalbach, Germany) according to the
manufacturers’ instructions.
2.4.2. Evaluation of eWAT Redox Status. A piece of frozen
eWAT was homogenized in a RIPA lysis buffer (pH 7.5; Cell
Signaling Technology®, Beverly, MA) containing protease
and phosphatase inhibitor cocktails (Roche®, Mannheim,
Germany). Total protein levels were determined by the
Bradford assay [21]. The eWAT catalase activity was mea-
sured according to Xu and colleagues [22], and enzyme
activity was expressed in μmol·min·mL-1 per eWAT protein
(mg·mL-1) [21]. Total superoxide dismutase (SOD) activity
was assessed with a commercial colorimetric kit (#19160,
Sigma®, Seelze, Germany) following the manufacturer’s
instructions. Lipid peroxidation in eWAT was determined
by measuring the thiobarbituric acid reactive substances
(TBARS), as a marker of oxidative stress, mainly malondial-
dehyde (MDA). The quantification was performed accord-
ing to Ohkawa et al. [23] with modifications, as previously
described [24]. Data were normalized per total protein con-
centration, measured by Bradford [21] and expressed as
nM·mg protein-1.
Hydrogen peroxide (H2O2) was measured by fluores-
cence using the Amplex® UltraRed hydrogen peroxide
(10-acetyl-3,7-dihydroxiphenoxazine) assay (Invitrogen®,
Paisley, United Kingdom) as described [24].
2.4.3. Gene Expression in Epididymal White Adipose Tissue.
Gene expression was determined by real-time quantitative
polymerase chain reaction (qPCR). Briefly, total RNA was
isolated from epididymal white adipose tissue (eWAT) by
using trizol (TRizol® Reagent, Darmstadt, Germany), quan-
tified by spectrophotometry, and 1μg was used for the syn-
thesis of cDNA by reverse transcriptase (Invitrogen®).
Subsequently, the product was amplified using the GoTaq
qPCR Master Mix (Promega®; Mannheim, Germany) by
real-time quantitative PCR (ABI 7900HT Real-Time PCR
System-Applied Biosystems®, Darmstadt, Germany). mRNA
was quantified as a relative value compared with an internal
reference, GAPDH. Quantitative values for mRNA expres-
sion were obtained by the parameter 2−ΔΔCt method [25].
The primers used for real-time quantitative PCR are listed
in Table 1.
2.4.4. Histological Analysis in eWAT. Small fragments of
eWAT was fixed in 4% buffered formaldehyde, embedded
in paraffin, and sectioned at 10μm. H&E images were used
for the determination of mean adipocyte size and macro-
phage count. The sections were observed under an Olympus
BX51 attached DP70 Digital Camera System (Tokyo, Japan);
the fields were evaluated with final magnification of 20x
(50μm). Digital photographs were taken from each section,
adipocyte size expression were quantified using the “ImageJ”
image processing software (NIH, Bethesda, MD, USA), and
the macrophage count was performed on the average of 4
fields per animal (macrophage/field) [26–28].
2.5. Data Analysis. Results are expressed as mean ± SEM,
and “n” indicates the number of animals used in the exper-
iment. The dose-response curves of the different groups
were compared by two-way ANOVA followed by Bonferro-
ni’s correction. One-way ANOVA was used for other com-
parisons followed by Bonferroni tests using GraphPad
Prism® version 5.0 for Windows. A value of p < 0:05 was
considered significant.
3. Results
3.1. ATZ Decreases Body Weight, WAT Depots, Lipid Profile,
and Blood Pressure in High Fat-InducedMetS Mice.MetS was
induced in mice by HFD for 20 weeks. At week 8, one group
was additionally treated with 500mg · kg−1 24 h−1 of ATZ.
The HFD group showed a significant increase in body weight
from the third until the 20th week of HFD consumption com-
pared to the control (Figure 1(a)). Strikingly, after one week
of ATZ treatment until the end of the experimental protocol
(from the 9th week until 20th week), the body weight
decreased significantly compared to the HFD group
(Figure 1(a) and Table 2). The data demonstrate the effect
of HFD on body weight gain, as well as the effect of ATZ
on weight loss. Due to the higher caloric and lipid content
of HFD, food intake was reduced in both groups fed a HFD
irrespective of ATZ treatment. Tibia length and total plasma
protein were similar between the groups (Table 2).
After HFD consumption, the systolic blood pressure,
WAT index, and epididymal and perirenal adipose tissue
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increased significantly compared to the control (CT) group.
However, after ATZ treatment, all of these parameters were
significantly reduced (Figure 1(b) and Table 2). On the
other hand, brown adipose tissue significantly increased
only in the HFD+ATZ group (Table 2), suggesting a prob-
able action of ATZ treatment in adipocyte differentiation
and thermogenesis.
The expression of mRNA for adiponectin in WAT was
significantly decreased in both, the HFD and HFD+ATZ
groups compared to CT (Figure 1(c)). Consistently with the
increased amount of visceral WAT and an unchanged
mRNA level (Figure 1(d)), the plasma levels of leptin were
significantly higher in HFD animals (Figure 1(e)). Interest-
ingly, in HFD+ATZ mice, both protein and gene expressions
of leptin were significantly lower compared to the HFD
group (Figures 1(d) and 1(e), respectively).
The fasting plasmatic levels of TCOL and nonesterified
fatty acid (NEFA) were significantly increased in the HFD
group compared to CT, with no changes in TG levels
(Table 2). Concurrent with the decrease in fat depots, the
levels of TG and NEFA, but not TCOL, were also significantly
decreased in the HFD+ATZ group (Table 2).
The lipolytic activity of WAT was measured in vivo by
stimulation with CL-316,243 hydrate, a selective β3-adreno-
ceptor agonist. The release of NEFA was significantly lower
over time (15 and 30 minutes after stimulation) in the HFD
group compared to the CT group (Figure 2(a)). In contrast,
NEFA release was significantly higher before and 15 and 30
minutes after stimulation in the HFD+ATZ group than in
the HFD group and indistinguishable from controls, which
could explain the lower fat depot in these animals. The data
demonstrate the decrease in lipolysis induced by HFD, as
well as the increase in this parameter induced by ATZ. The
basal NEFA at time point 0 was different among the three
groups because it was normalized by the WAT index
(mmol/L·WAT index-1), which is different among groups.
In order to determine the influence of ATZ, catalase, and
H2O2 separately, the same lipolysis assay was performed
in vitro in eWAT. The results showed no significant differ-
ence at baseline and after 90 and 180 minutes of stimulation
between the groups that received only CL-316,243 hydrate or
associated with ATZ, catalase, or H2O2 (Figure 2(b)), sug-
gesting that the elevated lipolysis induced by ATZ in vivo
does not involve the direct action of these substances on the
breakdown of triglycerides within adipocytes.
Analysis of the expression of genes involved in lipolysis
showed that HFD induced a significant decrease in adrenergic
β3-receptor (β3), lipoprotein lipase (LPL), and hormone-
sensitive lipase (HSL) mRNA in WAT (Figures 2(c)–2(e)).
ATZ treatment decreased even further the levels of β3 mRNA
but did not change LPL mRNA expression compared to the
HFD group (Figures 2(c) and 2(d)). However, HSL mRNA
expression was significantly higher in the HFD+ATZ animals
than in the HFD group (Figure 2(e)), which could explain the
increased lipolysis induced by ATZ in vivo, since HSL is a
lipolytic enzyme responsible for the breakdown of triglycer-
ides stored in adipocytes to free fatty acids.
Histological analysis of eWAT showed a significant
increase in the adipocyte diameter after HFD consumption,
Table 1: Primer sequences used for real-time quantitative PCR
(amplicons between 100 and 150 bp).
Primers Sequence forward and reverse (5′–3′)
Adiponectin
F: GGAACTTGTGCAGGTTGGAT
R: CCTTCAGCTCCTGTCATTCC
Adrβ3
F: GCTGACTTGGTAGTGGGACTC
R: TAGAAGGAGACGGAGGAGGAG
Caspase 1
F: ACCCTCAAGTTTTGCCCTTT
R: GATCCTCCAGCAGCAACTTC
Catalase
F: CACGCTGGTAGTTGGCCACT
R: GCCCAGCCCTGACAAAATGC
CCL2
F: GCCAACTCTCACTGAAGCC
R: GCTGGTGAATGAGTAGCAGC
CD68
F: TAGGACCGCTTATAGCCCAAG
R: CTGTAGGTGTCATCGTGAAG
CIDEA
F: GCAGCCTGCAGGAACTTATC
R: CCGATTTCTTTGGTTGCTTG
GAPDH
F: CCATCACCATCTTCCAGGAG
R: GTGGTTCACACCCATCACAA
GLUT4
F: TGATTCTGCTGCCCTTCTGT
R: GGACATTGGACGCTCTCTCT
HSL
F: ACGGATACCGTAGTTTGGTGC
R: TCCAGAAGTGCACATCCAGGT
IR
F: CCACCAATACGTCATTCACAAC
R: GGGCAGATGTCACAGAATCAA
Interleukin-1β
F: GCCACCTTTTGACAGTGATGAG
R: CCTGAAGCTCTTGTTGATGTGC
Interleukin 18
F: TCTGACATGGCAGCCATTGT
R: CAGGCCTGACATCTTCTGCAA
Lep
F: CGTGTGTGAAATGTCATTGATCCT
R: GACACCAAAACCCTCATCAAGAC
LPL
F: AGTGGCCGAGAGCGAGAAC
R: CCACCTCCGTGTAAATCAAGAAG
PPARγ
F: TCAGCTCTGTGGACCTCTCC
R: ACCCTTGCATCCTTCACAAG
RevErbα
F: TGGCCTCAGGCTTCCACTATG
R: CCGTTGCTTCTCTCTCTTGGG
SOD1
F: GACGGTGTGGCCAATGTGTC
R: CAAGCGGCTCCCAGCATTTC
TNF-α
F: GTCTACTGAACTTCGGGGTGA
R: CTCCTCCACTTGGTGGTTTG
UCP2
F: GCATTGGCCTCTACGACTCT
R: GTCCTGGTATCTCCGACCAC
Adrβ3: adrenergic β3 receptor; CCL2 or MCP1: monocyte chemoattractant
protein 1; CD68: cluster of differentiation 68; CIDEA: cell death activator;
GAPDH: glyceraldehyde 3-phosphate dehydrogenase; GLUT4: glucose
transporter type 4; HSL: hormone-sensitive lipase; IR: insulin receptor; Lep:
leptin; LPL: lipoprotein lipase; PPARγ: peroxisome proliferator-activated
receptor gamma; RevErbα or NR1D1: nuclear receptor subfamily 1; SOD1:
superoxide dismutase 1; TNF-α: tumor necrosis factor alpha; UCP2:
uncoupling protein 2.
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indicating large accumulation of triglycerides. ATZ pre-
vented this effect and even induced marked atrophy and an
accumulation of macrophages in this tissue (Figures 3(a)–
3(e)).
3.2. ATZ Modulates Markers of Inflammation, Cell Death,
Adipogenesis, and Oxidative Status in eWAT. We next
hypothesized that the marked atrophy in eWAT after ATZ
treatment could be due to the activation of pathways involved
in inflammation, cell death, inhibition of adipogenesis, and/or
high oxidative stress. Related to the inflammatory pathway,
the gene expression of cluster of differentiation 68 (CD68),
monocyte chemoattractant protein 1 (MCP1 or CCL2), and
interleukin-1β (IL-1β) was significantly increased in the
HFD group compared to the CT group, and the ATZ treat-
ment increased it even more (Figures 4(a), 4(b), and 4(e),
respectively). The amount of mRNA for caspase 1, tumor
necrosis factor alpha (TNF-α), and IL-18 was not different
between CT and HFD, but ATZ treatment significantly
increased their levels compared to HFD (Figures 4(c), 4(d),
and 4(f), respectively). The mRNA for CIDEA, a cell death
marker, and also for PPARγ (peroxisome proliferator-
activated receptor gamma) and RevErbα, both involved in
adipogenesis, were significantly decreased in the HFD com-
pared to the CT group. However, in the ATZ group, the
expression of these genes increased significantly compared
to the HFD group (Figures 4(g)–4(i), respectively).
In the evaluation of the redox profile, mRNA for SOD1
(the Cu-Zn-cytoplasmic isoform) and catalase were signifi-
cantly decreased in the HFD compared to the CT group
(Figures 5(a) and 5(b)). However, the gene expression of
mitochondrial uncoupling protein 2 (UCP2), an anion car-
rier protein, showed no significant differences between the
HFD group and the CT group (Figure 5(c)). ATZ treatment
significantly further decreased SOD expression in eWAT.
Interestingly, catalase and UCP2 mRNA expression were
increased even compared to the control group (Figures 5(b)
and 5(c)). Despite changes in its mRNA, total SOD activity
in eWAT was not different between the groups (Figure 5(d)).
Catalase activity was slightly decreased after ATZ treatment
despite upregulation of its mRNA (Figure 5(e)). Lipid perox-
idation, measured by TBARS levels in eWAT, was decreased
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Figure 1: (a) Body weight during the weeks of treatment (g); (b) WAT index (%); (c, d) relative gene expression of adiponectin and leptin,
respectively, in epididymal white adipose tissue (eWAT) (arbitrary units); (e) leptin levels in plasma (ng·mL-1) of C57BL/6 mice after dietetic
intervention (chow and high-fat) and oral treatment with ATZ (500mg·kg-1). Each point on the graph represents themean ± SEM. ANOVA
(two-way): ∗∗p < 0:001; ∗∗∗p < 0:001 HFD vs. CT; §p < 0:05; §§§p < 0:001 HFD+ATZ vs. HFD. Each bar graph represents the mean ± SEM.
ANOVA (one-way): ∗p < 0:05, ∗∗p < 0:01, and ∗∗∗p < 0:001.
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Table 2: General characteristics from control, HFD, and HFD+ATZ (500mg·kg-1) treated mice.
Parameter
Groups
CT HFD HFD+ATZ
Final systemic fasting glucose 103:3 ± 7:1 180:2 ± 13:86a 154:5 ± 5:65c
Food intake (g/body weight·day-1) 0:16 ± 0:00 0:081 ± 0:00a 0:08 ± 0:00
Final body weight (g) 32:19 ± 0:27 47:87 ± 1:41a 27:83 ± 0:20b,c
Δ body weight (final minus basal) 10:95 ± 0:51 25:69 ± 0:89a 7:99 ± 0:59b,c
Δ body weight (g) (final minus start of ATZ treatment) 3:78 ± 0:63 7:40 ± 0:77a −7:31 ± 0:90b,c
Systolic blood pressure 118:0 ± 2:44 134:8 ± 5:16a 118:9 ± 3:27b
Epididymal adipose tissue (%) 1:36 ± 0:13 3:05 ± 0:19a 0:26 ± 0:06b,c
Perirenal adipose tissue (%) 0:67 ± 0:18 1:67 ± 0:22a 0:08 ± 0:02b,c
Brown adipose tissue (%) 0:32 ± 0:03 0:33 ± 0:01 0:84 ± 0:04b,c
Total cholesterol (mg·dL-1) 85:78 ± 2:84 135:6 ± 10:59a 110:3 ± 20:26
Triglycerides (mg·dL-1) 57:70 ± 8:6 83:98 ± 15:04 41:51 ± 8:7b
Nonesterified fatty acid (NEFA-mmol·L-1) 0:38 ± 0:04 0:60 ± 0:05a 0:17 ± 0:0b,c
Right tibia (mm) 18:1 ± 0:01 17:8 ± 0:03 18:4 ± 0:02
Total plasma proteins (mg·mL-1) 7:96 ± 0:07 8:13 ± 0:14 8:01 ± 0:05
Values represent the mean ± SEM. ANOVA one-way: ap < 0:05 HFD vs. CT. bp < 0:05 HFD+ATZ vs. HFD. cp < 0:05 HFD+ATZ vs. CT.
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Figure 2: (a, b) NEFA release after lipolysis in vivo (mmol.L-1·WAT index-1) and in vitro (mmol.L-1), respectively; (c–e) relative gene
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by ATZ treatment in the HFD groups (Figure 5(f)). On the
other hand, the levels of H2O2 in eWAT were equally
decreased in the HFD and HFD+ATZ groups compared to
the CT group (Figure 5(g)).
3.3. ATZ Ameliorates High-Fat Diet-Induced Impairment in
Glucose Metabolism. Fasting blood glucose was clearly
increased in both groups fed with HFD (Table 2). Glucose
tolerance was impaired after HFD consumption but not
when the animals were treated with ATZ (Figure 6(a)); this
is observed by the significant increase in the glycemic curve
over time in the HFD group compared to the CT group, as
well as the significant decrease in the same curve in the
HFD+ATZ group compared to the HFD group, evidencing
the opposite effect of HFD and ATZ on glucose tolerance.
The mRNA for GLUT4 in eWAT was significantly decreased
in the HFD group compared to the CT group, and ATZ
attenuated this effect (Figure 6(b)). Accordingly, the increase
in insulin resistance observed by the significant increase in
the glycemic curve over time in HFD animals was also atten-
uated in the ATZ-treated group, although not significantly
compared to the HFD group (Figure 6(c)). The gene expres-
sion of insulin receptor in eWAT was not different between
the groups (Figure 6(d)). Nevertheless, the TyG index and
plasmatic insulin levels were significantly higher in the
HFD than in the CT group, and ATZ significantly reduced
these parameters (Figures 6(e) and 6(f)). Together, these data
suggest that ATZ ameliorates HFD-induced impairment of
glucose metabolism.
4. Discussion
Long-term oral treatment with ATZ provides strong reduc-
tion both in fat deposition and in body weight in HFD-
induced obesity mice, accompanied by an improved lipid
and glucose metabolism.
We consider two pathways by which ATZ could induce
the strong fat loss: in a first line of reasoning, the catalase
inhibition and, consequently, the increase in H2O2 levels, or
in a second line of reasoning, the blocking of heme synthesis
by inhibiting aminolevulinic acid dehydratase.
The role of catalase in adiposity is still controversial. On
the one hand, catalase overexpression in fat inhibits adiposity
[29]. On the other hand, knockout animals for catalase show
different metabolic profiles according to the literature. The
work of Park et al. [9] shows no effect of catalase knockout
on body weight and epididymal fat mass either under normal
diet or HFD conditions compared to wild type. However,
plasma-free fatty acids and triglycerides were increased in
catalase knockout animals [9]. Heit et al. [30], in turn,
showed that catalase knockout animals presented an increase
in body weight and serum triglycerides, despite no difference
in WAT weight between wild-type and knockout mice. Our
findings identify the opposite after ATZ treatment: the ani-
mals decreased all parameters related to HFD-induced obe-
sity, although catalase activity was not completely inhibited
in WAT, which supported our second line of reasoning for
the mechanism of action for ATZ: heme synthesis inhibition
which, in turn, blocks adipogenesis.
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Figure 3: Photomicrographs of a section of the epididymal adipose tissue show the adipocytes after staining with hematoxylin-eosin (HE; (a)
CT, (b) HFD, and (c) HFD+ATZ); (b) adipocyte with triglyceride accumulation confirmed by the larger diameter of the cell (vs.CT group); (c)
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ATZ is an inhibitor of heme biosynthesis [31], which, in
turn, leads to blockage of adipogenesis probably by activation
of nuclear receptor RevErbα [14, 32]. Under HFD, this pro-
cess leads to apoptosis of adipocytes, followed by the invasion
of inflammatory cells. The increase in NEFA release, as evi-
denced by lipolysis in vivo, a marked atrophy in WAT, and
the decrease in adipocyte diameter are consequences of
blocking adipogenesis, enhanced inflammation, and apopto-
sis induced by ATZ. Also, most of our gene expression data
for inflammatory and cell death markers fit to this scenario:
increase in CD68, CCL2, caspase 1, TNF-α, IL-1β, IL-18,
and CIDEA in WAT. In addition, the WAT of the ATZ
group presented a high amount of macrophages. During adi-
pose tissue inflammatory response, such as that occurring in
obese WAT, CCL2 binds its receptor CCR2 activating the
monocyte transmigration and differentiation intoM1macro-
phages. The classical M1 pathway induces the production of
proinflammatory cytokines (for example, IL-1β, IL-6, and
TNF-α) [33, 34], which concur with the scenario observed
in WAT of the ATZ-treated group. Corroborating the find-
ings of our data, Park et al. [9], who used knockout mice
for catalase, as well as mice that received ATZ as a pharmaco-
logical inhibitor of catalase, showed macrophage infiltration
into WAT [9].
Functioning as a RevErbα ligand, heme is an impor-
tant signaling molecule for the induction of adipogenesis
[35]. Our hypothesis is that ATZ may interfere with the
adipogenic programming probably by activation of nuclear
receptor RevErbα, a pivotal player in adipocyte differentia-
tion [14, 35]. Fontaine et al. [36] identified the gene of
RevErbα as a target for nuclear receptor PPARγ [37–39]
in adipogenesis and as a modulator of adipocyte function.
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Figure 4: Relative gene expression of (a) CD68, (b) CCL2, (c) caspase 1, (d) TNF-α, (e) interleukin-1β, (f) interleukin 18, (g) CIDEA, (h)
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with ATZ (500mg·kg-1). Each bar graph represents the mean ± SEM. ANOVA (one-way): ∗p < 0:05, ∗∗p < 0:01, and ∗∗∗p < 0:001.
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PPARγ hypomorphic mice (PPARγhyp/hyp) presented neona-
tal mortality; the surviving animals exhibited a lipodystro-
phy, with moderate glucose intolerance but not a fatty liver,
and compensatory regulation of genes in the muscle that
allowed the oxidation of lipid excess [40]. On the other hand,
adipose-specific PPARγ knockout causes insulin resistance in
the fat and liver, and these animals are more susceptible to
HFD-induced insulin resistance and steatosis [37]. Together,
these studies highlight the relevance of PPARγ in lipid and
glycemic metabolism, as well as support the idea that the
observed improvement of these pathways in obese animals
treated with ATZ may be a reflection of the high level of
PPARγ associated with fat loss.
Wang and Lazar [14] identified a bifunctional role of
RevErbα in adipocyte differentiation in vitro. Their work
showed that during adipogenesis, the mRNA increases but
protein expression behaves differently: during the initial stages
of differentiation it increases, because of being required for
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Figure 5: (a–c) Relative gene expression of SOD1, catalase, and UCP2 in WAT (arbitrary units), respectively; (d) SOD activity (UI/protein,
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(500mg·kg-1). Each bar graph represents the mean ± SEM. ANOVA (one-way): ∗p < 0:05, ∗∗p < 0:01, and ∗∗∗p < 0:001:
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the early mitogenic event during 3T3-L1 cell adipogenesis.
Still, at later stages, RevErbα protein levels are decreased,
because its degradation is necessary for continued differenti-
ation, since it inhibits the adipogenic programming by
repressing the expression of PPARγ. According to these data,
we would expect an increase in the gene expression of
RevErbα and a decrease in PPARγ, but both were increased
in the ATZ group, suggesting that the augmentation of
PPARγ is compensatory to the drastic loss of fat. Accord-
ingly, data from our group showed that mice treated for 5
days with ATZ exhibited decreased PPARγ mRNA in WAT
(data not shown), confirming that PPARγ expression is
indeed suppressed in the beginning of treatment.
As a result of fat loss and probably also the increase in
PPARγ, previously discussed, the animals treated with ATZ
showed improvement in several parameters that were
impaired by consumption of HFD: the decrease in leptin
plasma levels and gene expression inWAT, regulating energy
intake and expenditure [41]; the increase in HSL gene expres-
sion, contributing to lipolysis [42]; the increased BAT
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Figure 6: (a) Blood glucose levels in the glucose tolerance test (mg·dL-1); (b) relative gene expression of GLUT4 in eWAT (arbitrary units); (c)
blood glucose levels in the insulin tolerance test (mg·dL-1); (d) relative gene expression of insulin receptor (IR) in eWAT (arbitrary units); (e)
insulin resistance (TyG index); (f) insulin levels in plasma (ng·mL-1) of C57BL/6 mice after dietetic intervention (chow and high-fat) and oral
treatment with ATZ (500mg·kg-1). Each point on the graph represents the mean ± SEM. ANOVA (two-way): ∗∗p < 0:01; ∗∗∗p < 0:001 HFD
vs. CT; §§p < 0:01; §§§p < 0:001 HFD+ATZ vs. HFD. Each bar graph represents the mean ± SEM. ANOVA (one-way): ∗p < 0:05, ∗∗p < 0:01,
and ∗∗∗p < 0:001.
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Figure 7: Proposed mechanism by which ATZ acts: in the context of HFD-induced obesity and metabolic syndrome in mice (HFD-model),
ATZ treatment probably induces heme synthesis inhibition/decrease (1), which blocks adipogenesis by increasing RevErbα gene expression
and, possibly, decreasing RevErbα activity (2), leading to apoptosis of adipocytes, evidenced by the increases in mRNA for caspase 1 and cell
death activator (CIDEA) (3). This condition promotes inflammatory cell infiltration in epididymal white adipose tissue (eWAT), confirmed
by the increased expression of marker genes: cluster of differentiation 68 (CD68), monocyte chemoattractant protein 1 (MCP1 or CCL2),
tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β), and interleukin 18 (IL-18) (4), inducing atrophy in eWAT, as well as the
decreases in adipocyte diameter and WAT index (5). As a consequence of fat loss, ATZ elicits a beneficial systemic antiobesity effect and
improves the metabolic status by increasing lipolysis in vivo, peroxisome proliferator-activated receptor gamma (PPARγ), glucose
transporter 4 (GLUT4), and hormone-sensitive lipase (HSL) genes, as well as by decreasing lipid peroxidation (TBARS), catalase activity,
and mRNA for leptin, adiponectin, and beta-3 adrenergic receptor (Adr-β3 receptor) in eWAT. In addition, systemically, ATZ decreases
insulin, leptin, nonesterified fatty acid (NEFA), triglyceride (TG) levels, and blood pressure, which results in the improvement of glucose
tolerance and insulin sensitivity (6).
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amount, which may reflect on thermogenic improvement
[43]; the amelioration of insulin and glucose regulation evi-
denced by the decrease in glucose intolerance, insulin resis-
tance, and insulin plasma levels, as well as the increase in
GLUT4 expression in WAT, the main glucose transporter
expressed in adipose tissue [44]; and the decrease in plasma
lipid levels. Moreover, the ATZ treatment decreased the liver
weight, which may reflect the decrease in hepatic lipid depo-
sition (HFD = 0:0960 ± 0:01 vs.HFD + ATZ = 0:0695 ± 0:01;
p < 0:05). ATZ decreased the adiponectin mRNA in WAT;
we consider two alternatives to explain: in a first line of rea-
soning, it could be attributed to the drastic decrease in the
WAT index, or in a second line of reasoning, the blocking
of adipogenesis, which also interferes with the production
of anti-inflammatory cytokines such as adiponectin. In addi-
tion, the increase in catalase and the decrease in SOD gene
expression in WAT could indicate a compensatory mecha-
nism related to the partial inhibition of catalase. Interest-
ingly, chronic ATZ-treatment diminished HFD-induced
lipid peroxidation, a marker for oxidative stress [5].
The heme hypothesis is not consistent with all data. It is
possible that ATZ performed a mixed action in adipose tis-
sue. Thus, we cannot discard other ATZ effects, such as inhi-
bition of acetyl-CoA carboxylase and thereby fatty acid
synthesis in the liver [45], which can contribute to the
decrease in lipid depots. Nevertheless, the exact mechanism
involved in the ATZ action in body weight and WAT depots,
as well as in redox signaling, be it local or systemic, needs
more investigations.
Collectively, we show that ATZ induces quick and strong
fat loss probably through heme synthesis inhibition which
blocks adipogenesis by probably decreasing RevErbα activ-
ity. As a consequence, adipocytes become apoptotic, which
leads to the recruitment of macrophages and inflammation
in WAT. This strong antiobesity effect of ATZ together with
the low toxicity of this compound [46], and the beneficial
secondary effects on blood pressure, lipid and glucose
metabolism, could make it a new treatment option for both
obesity and MetS. According to the results of the present
work, Figure 7 highlights the proposed mechanism by which
ATZ acts.
5. Summary
Our findings give new insight into the action of ATZ on lipid
metabolism. Considering its low toxicity, ATZ could repre-
sent an old compound with novel mechanisms of action to
be studied for the treatment of both obesity and metabolic
syndrome.
Abbreviations
Adrβ3: Beta-3 adrenergic receptor
ATZ: 3-Amino-1,2,4-triazole
BAT: Brown adipose tissue
BIH: Berlin Institute of Health
CD68: Cluster of differentiation 68
CIDEA: Cell death activator
CT: Control
DZHK: German Center for Cardiovascular
Research
eWAT: Epididymal white adipose tissue
FANUT: Faculdade de Nutrição
GLUT4: Glucose transporter 4
H2O2: Hydrogen peroxide
HFD: High-fat diet
HSL: Hormone-sensitive lipase
ICBS: Instituto de Ciências Biológicas e da
Saúde
IL-1β: Interleukin 1β
IL-18: Interleukin 18
IR: Insulin receptor
LPL: Lipoprotein lipase
MCP1 or CCL2: Monocyte chemoattractant protein 1
MetS: Metabolic syndrome
NEFA: Nonesterified fatty acid
PPARγ: Peroxisome proliferator-activated
receptor gamma
RevErbα or NR1D1: Nuclear receptor subfamily 1
SOD: Superoxide dismutase
TBARS: Thiobarbituric acid reactive substances
TCOL: Total cholesterol
TG: Triglycerides
TNF-α: Tumor necrosis factor alpha
TyG index: Triglyceride and glucose levels index
UCP2: Uncoupling protein
UFAL: Universidade Federal de Alagoas
UFPE: Universidade Federal de Pernambuco
WAT: White adipose tissue.
Data Availability
The data used to support the findings of this study are avail-
able from the corresponding author upon request.
Additional Points
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metabolic parameters.
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